DOCSLIB.ORG

Innate Immunity and Inflammation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Innate Immunity and Inflammation ISBTc ‐ Primer on Tumor Immunology and Biological Therapy of Cancer InnateInnate ImmunityImmunity andand InflammationInflammation WillemWillem Overwijk,Overwijk, Ph.D.Ph.D. MDMD AndersonAnderson CancerCancer CenterCenter CenterCenter forfor CancerCancer ImmunologyImmunology ResearchResearch Houston,Houston, TXTX www.allthingsbeautiful.com InnateInnate ImmunityImmunity andand InflammationInflammation • Definitions • Cells and Molecules • Innate Immunity and Inflammation in Cancer • Bad Inflammation • Good Inflammation • Therapeutic Implications InnateInnate ImmunityImmunity andand InflammationInflammation • Definitions • Cells and Molecules • Innate Immunity and Inflammation in Cancer • Bad Inflammation • Good Inflammation • Therapeutic Implications • Innate Immunity: Immunity that is naturally present and is not due to prior sensitization to an antigen; generally nonspecific. It is in contrast to acquired/adaptive immunity. Adapted from Merriam‐Webster Medical Dictionary • Innate Immunity: Immunity that is naturally present and is not due to prior sensitization to an antigen; generally nonspecific. It is in contrast to acquired/adaptive immunity. • Inflammation: a local response to tissue injury – Rubor (redness) – Calor (heat) – Dolor (pain) – Tumor (swelling) Adapted from Merriam‐Webster Medical Dictionary ““InnateInnate ImmunityImmunity”” andand ““InflammationInflammation”” areare vaguevague termsterms •• SpecificSpecific cellcell typestypes andand moleculesmolecules orchestrateorchestrate specificspecific typestypes ofof inflammationinflammation ““InnateInnate ImmunityImmunity”” andand ““InflammationInflammation”” areare vaguevague termsterms •• SpecificSpecific cellcell typestypes andand moleculesmolecules orchestrateorchestrate specificspecific typestypes ofof inflammationinflammation •• InnateInnate ImmunityImmunity AA ≠≠ InnateInnate ImmunityImmunity BB •• InflammationInflammation AA ≠≠ InflammationInflammation BB CD4CD4++ TT cellcell Zhou et al., Immunity, 2009 CD4CD4++ TT cell:cell: Th1Th1 oror Th2?Th2? Zhou et al., Immunity, 2009 CD4CD4++ TT cell:cell: Th1Th1 oror Th2?Th2? Zhou et al., Immunity, 2009 CD4CD4++ TT cell:cell: Th1Th1 oror Th2Th2 oror Th17Th17 oror Th9Th9 oror TregTreg oror TfhTfh oror ?? Zhou et al., Immunity, 2009 Today,Today, thethe termterm ““CD4CD4++ TT cellcell”” cancan meanmean manymany thingsthings Zhou et al., Immunity, 2009 ““InnateInnate ImmunityImmunity”” andand ““InflammationInflammation”” cancan meanmean manymany thingsthings •• SpecificSpecific cellcell typestypes andand moleculesmolecules orchestrateorchestrate specificspecific typestypes ofof inflammationinflammation •• InnateInnate ImmunityImmunity AA ≠≠ InnateInnate ImmunityImmunity BB •• InflammationInflammation AA ≠≠ InflammationInflammation BB •• SomeSome immuneimmune responsesresponses promotepromote cancer,cancer, othersothers suppresssuppress itit InnateInnate ImmunityImmunity andand InflammationInflammation Functions: • Rapid response to tissue damage • Limit spread of infection • Initiate adaptive immune response (T, B) • Initiate tissue repair InnateInnate ImmunityImmunity andand Inflammation:Inflammation: AA PaperPaper CutCut Janeway, Immunobiology, 7th Ed. InnateInnate ImmunityImmunity andand Inflammation:Inflammation: AA PaperPaper CutCut Janeway, Immunobiology, 7th Ed. InnateInnate ImmunityImmunity andand Inflammation:Inflammation: AA PaperPaper CutCut Janeway, Immunobiology, 7th Ed. InnateInnate ImmunityImmunity andand Inflammation:Inflammation: AA PaperPaper CutCut Janeway, Immunobiology, 7th Ed. InnateInnate ImmunityImmunity andand InflammationInflammation • Definitions • Cells and Molecules • Innate Immunity and Inflammation in Cancer • Bad Inflammation • Good Inflammation • Therapeutic Implications InnateInnate ImmuneImmune Molecules:Molecules: CyclooxygenaseCyclooxygenase‐‐22 (COX(COX‐‐2)2) Recognize • inflammation Cause • inflammation InnateInnate ImmuneImmune Molecules:Molecules: ComplementComplement SystemSystem Recognize • pathogens • antibodies • lectins Cause • pathogen clearance • chemotaxis • inflammation Janeway, Immunobiology, 7th Ed. InnateInnate ImmuneImmune Molecules:Molecules: typetype II IFN(IFN(‐‐)) • Induced by infection/danger • Antiviral/Antiproliferative • Increase innate and adaptive immunity • Cause inflammation InnateInnate ImmuneImmune CellsCells Janeway, Immunobiology, 7th Ed. InnateInnate ImmuneImmune CellsCells Janeway, Immunobiology, 7th Ed. InnateInnate ImmuneImmune CellsCells Janeway, Immunobiology, 7th Ed. InnateInnate ImmuneImmune Cells:Cells: granulocytesgranulocytes ( ) Antigen Presentation Recognize Cause • pathogens • pathogen clearance • antibodies • inflammation Janeway, Immunobiology, 7th Ed. InnateInnate ImmuneImmune Cells:Cells: phagocytesphagocytes Monocyte Blood Recognize precursor of tissue Macrophages and • pathogens Dendritic Cells • antibodies Cause • pathogen clearance • adaptive immunity • inflammation Janeway, Immunobiology, 7th Ed. InnateInnate ImmuneImmune Cells:Cells: NK,NK, NKTNKT andand TT cellscells Recognize • pathogens • stressed cells • “altered self” Cause • pathogen clearance • stressed/abnormal cell clearance • inflammation DangerDanger signalssignals startstart inflammationinflammation PATHOGENS DAMAGE Rubartelli & Lotze, Trends in Immunology 2007 DangerDanger signalssignals startstart inflammationinflammation PATHOGENS DAMAGE Rubartelli & Lotze, Trends in Immunology 2007 ReceptorsReceptors sensesense Danger:Danger: PathogensPathogens Kawai & Akira, Nat. Immunol. 2010 ReceptorsReceptors sensesense Danger:Danger: DamageDamage Kawai & Akira, Nat. Immunol. 2010 InnateInnate ImmunityImmunity andand InflammationInflammation • Definitions • Cells and Molecules • Innate Immunity and Inflammation in Cancer • Bad Inflammation • Good Inflammation • Therapeutic Implications InnateInnate ImmunityImmunity andand InflammationInflammation inin CancerCancer • Outcomes vary: ‐ Promote cancer (Bad inflammation) ‐ Suppress cancer (Good inflammation) InnateInnate ImmunityImmunity andand InflammationInflammation • Definitions • Cells and Molecules • Innate Immunity and Inflammation in Cancer • Bad Inflammation • Good Inflammation • Therapeutic Implications BadBad InflammationInflammation CausesCauses CancerCancer DANGER cellular damage caused by • pathogens • physical damage • chemicals • UV • etc IMMUNE RESPONSE DANGER INFLAMMATION IMMUNE RESPONSE DANGER INFLAMMATION COLLATERAL DAMAGE IMMUNE RESPONSE DANGER INFLAMMATION COLLATERAL DAMAGE IMMUNE RESPONSE INFLAMMATION COLLATERAL DAMAGE IMMUNE RESPONSE DANGER INFLAMMATION COLLATERAL DAMAGE CHRONIC IMMUNE RESPONSE DANGER INFLAMMATION CHRONIC COLLATERAL DAMAGE CHRONIC CHRONIC IMMUNE RESPONSE DANGER INFLAMMATION CHRONIC COLLATERAL DAMAGE CANCER CHRONIC CHRONIC IMMUNE RESPONSE DANGER INFLAMMATION CHRONIC COLLATERAL DAMAGE CANCER CHRONIC CHRONIC IMMUNE RESPONSE DANGER INFLAMMATION CHRONIC COLLATERAL DAMAGE CANCER CHRONIC CHRONIC IMMUNE RESPONSE DANGER INFLAMMATION cancer: a “never‐healing wound” InflammationInflammation cancan PromotePromote Cancer:Cancer: collaborationcollaboration withwith KK‐‐rasras mutationmutation no smoking 4 cigarettes per day K‐ras mutation & normal myeloid cells Takahashi et al. , Cancer Cell 2010 InflammationInflammation cancan PromotePromote Cancer:Cancer: collaborationcollaboration withwith KK‐‐rasras mutationmutation no smoking 4 cigarettes per day K‐ras mutation K‐ras mutation & + normal myeloid cells IKK‐/‐ myeloid cells Takahashi et al. , Cancer Cell 2010 InflammationInflammation cancan PromotePromote Cancer:Cancer: collaborationcollaboration withwith KK‐‐rasras mutationmutation no smoking 4 cigarettes per day K‐ras mutation K‐ras mutation • ↓ NF‐B & + • ↓ pSTAT3 ‐/‐ normal myeloid cells IKK myeloid cells • ↓ IL‐6 • ↓ neutrophils • ↓ angiogenesis Takahashi et al. , Cancer Cell 2010 InflammationInflammation cancan PromotePromote Cancer:Cancer: collaborationcollaboration withwith HPVHPV E6/E7E6/E7 oncogeneoncogene TUMOR tumor‐induced ANTIBODIES De Visser et al., Cancer Cell 2005 Andreu et al., Cancer Cell 2010 InflammationInflammation cancan CauseCause MutationMutation Able to repair DNA days post acute gut inflammation Meira et al., J. Clin. Invest. 2008 InflammationInflammation cancan CauseCause MutationMutation Able to repair DNA days post acute gut inflammation Meira et al., J. Clin. Invest. 2008 InflammationInflammation cancan CauseCause MutationMutation Meira et al., J. Clin. Invest. 2008 InflammationInflammation cancan CauseCause MutationMutation deoxyguanosine 8‐hydroxydeoxyguanosine Meira et al., J. Clin. Invest. 2008 TumorsTumors cancan induceinduce badbad inflammationinflammation TumorsTumors cancan induceinduce badbad inflammationinflammation Spleen (no tumor) Spleen (subcut. tumor) Bronte et al., J. Immunol. 1999 TumorsTumors cancan induceinduce badbad inflammationinflammation Normal Tumors induce immune system bad inflammation + Blocks treatment T cell treatment Marigo et al., Immunity 2010 TumorsTumors cancan induceinduce badbad inflammationinflammation Normal Tumors induce immune system bad inflammation + Blocks treatment T cell treatment Cebpb‐deficient Tumors cannot induce immune system bad inflammation + Treatment works T cell treatment Marigo et al., Immunity 2010 TumorsTumors cancan induceinduce badbad inflammationinflammation Ugel et al., Curr. Opin. Pharmacol. 2010 TumorsTumors cancan induceinduce badbad inflammationinflammation OncogenicOncogenic STAT3STAT3 Yu et al., Nat. Rev. Cancer 2009 TumorsTumors cancan induceinduce badbad inflammationinflammation OncogenicOncogenic
Load more

Recommended publications
  • Influence of Infection and Inflammation on Biomarkers of Nutritional Status
    A2.4 INFLUENCE OF INFECTION AND INFLAMMATION ON BIOMARKERS OF NUTRITIONAL STATUS A2.4 Influence of infection and inflammation on biomarkers of nutritional status with an emphasis on vitamin A and iron David I. Thurnham1 and George P. McCabe2 1 Northern Ireland Centre for Food and Health, University of Ulster, Coleraine, United Kingdom of Great Britain and Northern Ireland 2 Statistics Department, Purdue University, West Lafayette, Indiana, United States of America Corresponding author: David I. Thurnham; [email protected] Suggested citation: Thurnham DI, McCabe GP. Influence of infection and inflammation on biomarkers of nutritional status with an emphasis on vitamin A and iron. In: World Health Organization. Report: Priorities in the assessment of vitamin A and iron status in populations, Panama City, Panama, 15–17 September 2010. Geneva, World Health Organization, 2012. Abstract n Many plasma nutrients are influenced by infection or tissue damage. These effects may be passive and the result of changes in blood volume and capillary permeability. They may also be the direct effect of metabolic alterations that depress or increase the concentration of a nutrient or metabolite in the plasma. Where the nutrient or metabolite is a nutritional biomarker as in the case of plasma retinol, a depression in retinol concentrations will result in an overestimate of vitamin A deficiency. In contrast, where the biomarker is increased due to infection as in the case of plasma ferritin concentrations, inflammation will result in an underestimate of iron deficiency. Infection and tissue damage can be recognized by their clinical effects on the body but, unfortunately, subclinical infection or inflammation can only be recognized by measur- ing inflammation biomarkers in the blood.
    [Show full text]
  • IFM Innate Immunity Infographic
    UNDERSTANDING INNATE IMMUNITY INTRODUCTION The immune system is comprised of two arms that work together to protect the body – the innate and adaptive immune systems. INNATE ADAPTIVE γδ T Cell Dendritic B Cell Cell Macrophage Antibodies Natural Killer Lymphocites Neutrophil T Cell CD4+ CD8+ T Cell T Cell TIME 6 hours 12 hours 1 week INNATE IMMUNITY ADAPTIVE IMMUNITY Innate immunity is the body’s first The adaptive, or acquired, immune line of immunological response system is activated when the innate and reacts quickly to anything that immune system is not able to fully should not be present. address a threat, but responses are slow, taking up to a week to fully respond. Pathogen evades the innate Dendritic immune system T Cell Cell Through antigen Pathogen presentation, the dendritic cell informs T cells of the pathogen, which informs Macrophage B cells B Cell B cells create antibodies against the pathogen Macrophages engulf and destroy Antibodies label invading pathogens pathogens for destruction Scientists estimate innate immunity comprises approximately: The adaptive immune system develops of the immune memory of pathogen exposures, so that 80% system B and T cells can respond quickly to eliminate repeat invaders. IMMUNE SYSTEM AND DISEASE If the immune system consistently under-responds or over-responds, serious diseases can result. CANCER INFLAMMATION Innate system is TOO ACTIVE Innate system NOT ACTIVE ENOUGH Cancers grow and spread when tumor Certain diseases trigger the innate cells evade detection by the immune immune system to unnecessarily system. The innate immune system is respond and cause excessive inflammation. responsible for detecting cancer cells and This type of chronic inflammation is signaling to the adaptive immune system associated with autoimmune and for the destruction of the cancer cells.
    [Show full text]
  • The Gut Microbiota and Inflammation
    International Journal of Environmental Research and Public Health Review The Gut Microbiota and Inflammation: An Overview 1, 2 1, 1, , Zahraa Al Bander *, Marloes Dekker Nitert , Aya Mousa y and Negar Naderpoor * y 1 Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Melbourne 3168, Australia; [email protected] 2 School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane 4072, Australia; [email protected] * Correspondence: [email protected] (Z.A.B.); [email protected] (N.N.); Tel.: +61-38-572-2896 (N.N.) These authors contributed equally to this work. y Received: 10 September 2020; Accepted: 15 October 2020; Published: 19 October 2020 Abstract: The gut microbiota encompasses a diverse community of bacteria that carry out various functions influencing the overall health of the host. These comprise nutrient metabolism, immune system regulation and natural defence against infection. The presence of certain bacteria is associated with inflammatory molecules that may bring about inflammation in various body tissues. Inflammation underlies many chronic multisystem conditions including obesity, atherosclerosis, type 2 diabetes mellitus and inflammatory bowel disease. Inflammation may be triggered by structural components of the bacteria which can result in a cascade of inflammatory pathways involving interleukins and other cytokines. Similarly, by-products of metabolic processes in bacteria, including some short-chain fatty acids, can play a role in inhibiting inflammatory processes. In this review, we aimed to provide an overview of the relationship between the gut microbiota and inflammatory molecules and to highlight relevant knowledge gaps in this field.
    [Show full text]
  • Discussion of Natural Killer Cells and Innate Immunity
    Discussion of natural killer cells and innate immunity Theresa L. Whiteside, Ph.D. University of Pittsburgh Cancer Institute Pittsburgh, PA 15213 Myths in tumor immunology • Cancer cells are ignored by the immune system • Immune responses are directed only against “unique” antigens expressed on tumor cells • Tumor-specific T cells alone are sufficient for tumor regression • Tumor are passive targets for anti-tumor responses Tumor/Immune Cells Interactions Tumor cell death C G DC M TUMOR NK Th B Tc Ab Ag Ag/Ab complex NK cells as anti-tumor effectors • LGL, no TCR, express FcγRIII, other activating receptors and KIRs • Spare normal cells but kill a broad range of tumor cells ex vivo by at least two different mechanisms • Produce a number of cytokines (IFN-γ, TNF-α) • Constitutively express IL-2Rβγ and rapidly respond to IL-2 and also to IL-15 and IFNα/β • Regulated by a balance of inhibitory receptors specific for MHC class I antigens and activating signals • NK-DC interactions at sites of inflammation Heterogeneity of human NK cells • Every NK cell expresses at least one KIR that recognizes a self MHC class I molecule • Two functionally distinct subsets: 1) 90% CD56dimCD16bright , highly cytotoxic, abundant KIR expression, few cytokines 2) 10% CD56brightCD16dim/neg, produce cytokines, poorly cytotoxic, low KIR expression Expression of activating and inhibitory receptors on NK cells Interaction with CD56 Interaction with MHC ligands non-MHC ligands KIR CD16 CD2 CD94/NKG2A/B β2 NKp46, 44, 30 CD94/NKG2C/E NK Cell 2B4 NKG2D Lair1 LIR/ILT A
    [Show full text]
  • COVID-19 Natural Immunity
    COVID-19 natural immunity Scientific brief 10 May 2021 Key Messages: • Within 4 weeks following infection, 90-99% of individuals infected with the SARS-CoV-2 virus develop detectable neutralizing antibodies. • The strength and duration of the immune responses to SARS-CoV-2 are not completely understood and currently available data suggests that it varies by age and the severity of symptoms. Available scientific data suggests that in most people immune responses remain robust and protective against reinfection for at least 6-8 months after infection (the longest follow up with strong scientific evidence is currently approximately 8 months). • Some variant SARS-CoV-2 viruses with key changes in the spike protein have a reduced susceptibility to neutralization by antibodies in the blood. While neutralizing antibodies mainly target the spike protein, cellular immunity elicited by natural infection also target other viral proteins, which tend to be more conserved across variants than the spike protein. The ability of emerging virus variants (variants of interest and variants of concern) to evade immune responses is under investigation by researchers around the world. • There are many available serologic assays that measure the antibody response to SARS-CoV-2 infection, but at the present time, the correlates of protection are not well understood. Objective of the scientific brief This scientific brief replaces the WHO Scientific Brief entitled “’Immunity passports’ in the context of COVID-19”, published 24 April 2020.1 This update is focused on what is currently understood about SARS-CoV-2 immunity from natural infection. More information about considerations on vaccine certificates or “passports”will be covered in an update of WHO interim guidance, as requested by the COVID-19 emergency committee.2 Methods A rapid review on the subject was undertaken and scientific journals were regularly screened for articles on COVID-19 immunity to ensure to include all large and robust studies available in the literature at the time of writing.
    [Show full text]
  • Cancer Immunology, Immunotherapy Editor-In-Chief: H
    Cancer Immunology, Immunotherapy Editor-in-Chief: H. Dong ▶ 94% of authors who answered a survey reported that they would definitely publish or probably publish in the journal again Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms. CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer 12 issues/year Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT),and Sociedad Española de Inmunologia- Electronic access Grupo Española de InmunoTerapia (SEI-GEIT). ▶ link.springer.com CIMT: http://www.cimt.eu/home Subscription information CCIC: http://www.immunotherapycancer.ca/ ▶ springer.com/librarians JACI: http://www.jaci.jp/eng/index.html NIBIT: http://www.nibit.org/index.php SEI-GEIT: http://www.inmunologia.org/grupos/home.php? UpOm5=M&Upfqym5uom=GK CITIM: http://www.canceritim.org Impact Factor: 6.968 (2020), Journal Citation Reports® On the homepage of Cancer Immunology, Immunotherapy at springer.com you can ▶ Sign up for our Table of Contents Alerts ▶ Get to know the complete Editorial Board ▶ Find submission information.
    [Show full text]
  • Prospects for NK Cell Therapy of Sarcoma
    cancers Review Prospects for NK Cell Therapy of Sarcoma Mieszko Lachota 1 , Marianna Vincenti 2 , Magdalena Winiarska 3, Kjetil Boye 4 , Radosław Zago˙zd˙zon 5,* and Karl-Johan Malmberg 2,6,* 1 Department of Clinical Immunology, Doctoral School, Medical University of Warsaw, 02-006 Warsaw, Poland; [email protected] 2 Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0310 Oslo, Norway; [email protected] 3 Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; [email protected] 4 Department of Oncology, Oslo University Hospital, 0310 Oslo, Norway; [email protected] 5 Department of Clinical Immunology, Medical University of Warsaw, 02-006 Warsaw, Poland 6 Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 86 Stockholm, Sweden * Correspondence: [email protected] (R.Z.); [email protected] (K.-J.M.) Received: 15 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Sarcomas are a group of aggressive tumors originating from mesenchymal tissues. Patients with advanced disease have poor prognosis due to the ineffectiveness of current treatment protocols. A subset of lymphocytes called natural killer (NK) cells is capable of effective surveillance and clearance of sarcomas, constituting a promising tool for immunotherapeutic treatment. However, sarcomas can cause impairment in NK cell function, associated with enhanced tumor growth and dissemination. In this review, we discuss the molecular mechanisms of sarcoma-mediated suppression of NK cells and their implications for the design of novel NK cell-based immunotherapies against sarcoma.
    [Show full text]
  • Engineered Marrow Macrophages for Cancer Therapy: Engorgement, Accumulation, Differentiation, and Acquired Immunity
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2017 Engineered Marrow Macrophages For Cancer Therapy: Engorgement, Accumulation, Differentiation, And Acquired Immunity Cory Alvey University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Pharmacology Commons Recommended Citation Alvey, Cory, "Engineered Marrow Macrophages For Cancer Therapy: Engorgement, Accumulation, Differentiation, And Acquired Immunity" (2017). Publicly Accessible Penn Dissertations. 2164. https://repository.upenn.edu/edissertations/2164 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2164 For more information, please contact [email protected]. Engineered Marrow Macrophages For Cancer Therapy: Engorgement, Accumulation, Differentiation, And Acquired Immunity Abstract The ability of a macrophage to engulf and break down invading cells and other targets provides a first line of immune defense in nearly all tissues. This defining ability ot ‘phagos’ or devour can subsequently activate the entire immune system against foreign and diseased cells, and progress is now being made on a decades-old idea of directing macrophages to phagocytose specific targets such as cancer cells. Physical properties of cancer cells influence phagocytosis and relate via cytoskeleton forces to differentiation pathways in solid tumors. Here, SIRPα on macrophages from mouse and human marrow was inhibited to block recognition of CD47, a ‘marker of self.’ These macrophages were then systemically injected into mice with fluorescent human tumors. Within days, the tumors regressed, and fluorescence analyses showed that the more the SIRPα-inhibited macrophages engulfed, the more they accumulated within tumors. In vitro phagocytosis experiments on transwells revealed that macrophage migration through micropores was inhibited by eating.
    [Show full text]
  • Immunotherapy, Inflammation and Colorectal Cancer
    cells Review Immunotherapy, Inflammation and Colorectal Cancer Charles Robert Lichtenstern 1,2, Rachael Katie Ngu 1,2, Shabnam Shalapour 1,2,* and Michael Karin 1,2,3 1 Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA; karinoffi[email protected] 2 Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA 3 Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA * Correspondence: [email protected] Received: 30 January 2020; Accepted: 3 March 2020; Published: 4 March 2020 Abstract: Colorectal cancer (CRC) is the third most common cancer type, and third highest in mortality rates among cancer-related deaths in the United States. Originating from intestinal epithelial cells in the colon and rectum, that are impacted by numerous factors including genetics, environment and chronic, lingering inflammation, CRC can be a problematic malignancy to treat when detected at advanced stages. Chemotherapeutic agents serve as the historical first line of defense in the treatment of metastatic CRC. In recent years, however, combinational treatment with targeted therapies, such as vascular endothelial growth factor, or epidermal growth factor receptor inhibitors, has proven to be quite effective in patients with specific CRC subtypes. While scientific and clinical advances have uncovered promising new treatment options, the five-year survival rate for metastatic CRC is still low at about 14%. Current research into the efficacy of immunotherapy, particularly immune checkpoint inhibitor therapy (ICI) in mismatch repair deficient and microsatellite instability high (dMMR–MSI-H) CRC tumors have shown promising results, but its use in other CRC subtypes has been either unsuccessful, or not extensively explored.
    [Show full text]
  • Principles of Tumour Immunology
    Principles of tumour immunology Michele Teng Nov 20th 2017, Singapore Cancer Immunoregulation and Immunotherapy Laboratory QIMR Berghofer MRI Brisbane, Australia [email protected] Disclosure Slide • I have received speakers bureau honoria from Merck Sharp & Dohme. Talk Outline 1. Hallmarks of Cancer 2. Cells of the Immune system 3. The Cancer Immunity Cycle - Tumor-associated antigens (TAA), Cellular and Humoral responses to TAA 4. Conceptual developments in the field of tumour immunology - Immunosurveillance and role of innate immunity, immune balance against cancer Sources of slide • Charles Janeway’s Immunobiology text book • Peer-reviewed articles (Pubmed) • Online slides ( URL listed) Cancer Hallmarks of Cancer (2000) Hanahan and Weinberg, Cell 2000 Emerging Hallmarks and Enabling Characteristics Hanahan and Weinberg, Cell 2011 Hallmarks of Cancer (2017) In Vitrogen Immunology (Study of the immune system) Cells of the immune system ILCs –innate lymphoid cells MAITs –Mucosal associated invariant T cells gd T cells – gamma delta T cells (ILCs) (gd, MAIT) Cancer Immunology (Study of the response of the immune system to cancer) The Cancer-Immunity Cycle – Steps to generate an effective anti-tumour response Chen and Mellman Immunity 2013 Not all cell deaths are equal (at priming an immune response) Cells can die in different ways DAMPs Tumour fragments Immunogenic Cell Death (ICD) DAMPs – Damage (Adjuvanticity, Antigenicity) associated molecular patterns Differential requirements for the immunogenicity of cell death TLR4 Nat Rev Immunol. 2017 Feb;17(2):97-111. doi: 10.1038/nri.2016.107. The Cancer-Immunity Cycle Immunity. 2013 Jul 25;39(1):1-10. doi: 10.1016/j.immuni.2013.07.012.
    [Show full text]
  • Understanding the Immune System: How It Works
    Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute NIH Publication No. 03-5423 September 2003 www.niaid.nih.gov www.nci.nih.gov Contents 1 Introduction 2 Self and Nonself 3 The Structure of the Immune System 7 Immune Cells and Their Products 19 Mounting an Immune Response 24 Immunity: Natural and Acquired 28 Disorders of the Immune System 34 Immunology and Transplants 36 Immunity and Cancer 39 The Immune System and the Nervous System 40 Frontiers in Immunology 45 Summary 47 Glossary Introduction he immune system is a network of Tcells, tissues*, and organs that work together to defend the body against attacks by “foreign” invaders. These are primarily microbes (germs)—tiny, infection-causing Bacteria: organisms such as bacteria, viruses, streptococci parasites, and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system’s job to keep them out or, failing that, to seek out and destroy them. Virus: When the immune system hits the wrong herpes virus target or is crippled, however, it can unleash a torrent of diseases, including allergy, arthritis, or AIDS. The immune system is amazingly complex. It can recognize and remember millions of Parasite: different enemies, and it can produce schistosome secretions and cells to match up with and wipe out each one of them.
    [Show full text]
  • Effect of Exercise Intensity on Cell-Mediated Immunity
    sports Perspective Effect of Exercise Intensity on Cell-Mediated Immunity Katsuhiko Suzuki 1,* and Harumi Hayashida 2 1 Faculty of Sport Sciences, Waseda University, 2-579-15 Mikajima, Tokorozawa 359-1192, Japan 2 Faculty of Culture and Sport Policy, Toin University of Yokohama, 1614 Kurogane-cho, Aoba-ku, Yokohama 225-8503, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-4-2947-6898 Abstract: Moderate-intensity exercise is considered to enhance immune function and to be useful for preventing acute upper respiratory infections and similar conditions. Many people practice low- intensity short-duration exercise with the expectation of a beneficial effect on immunocompetency. However, it is difficult to affirm the existence of definite evidence of such a benefit. In this article, we discuss the effects of low-intensity short-duration exercise on cell-mediated immunity, and contrast them to the effects of high-intensity and long-duration exercise. Whereas high-intensity exercise induces inflammation and reduces cell-mediated immune system function, low-intensity exercise does not appear to have a large effect on either inflammation or cell-mediated immune function. Low-intensity exercises such as walking and yoga, which are helpful to relieve stress, cannot be considered as harmful to the immune system. Although yoga was shown to impose fewer restrictions on breathing and physical strain, the evidence that yoga enhances cell-mediated immunity remains insufficient. Therefore, further studies are needed to examine the exercise mode that may be most effective for improvement of immune functions. Keywords: exercise; walking; yoga; cellular immune system; cytokines; inflammation 1.
    [Show full text]